F18-FLT PET/CT as a Tool for Assessment of Myeloablative Treatment in Patients With Acute Myeloid Leucemia(AML) (AML F18-FLT)

Hadassah Medical Center

Status: Unknown

Conditions: Acute Myeloid Leucemia

Study type: Observational

Funder types: Other

Identifiers

NCT01592266

0112-12-HMO

Details and patient eligibility

About

PET/CT is reliable tool in evaluation of treatment response in number cancers. F18-FLT is a precursor of DNA with high uptake in the bone marrow as a part of normal biodistribution. Highly increased uptake of this radiopharmaceutical was shown in a number of hematologic disease either in bone marrow or extramedullary.

F18-FLT PET/CT can provide a tool for whole body assessment of activity in bone marrow as well as early estimation of treatment efficacy or lack of it. In addition, this noninvasive study can replace bone marrow biopsy and predict response vs. non response to therapy.

Enrollment: 10 estimated patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• new diagnosis of AML

Exclusion criteria

• pregnancy

Trial design

10 participants in 1 patient group

AML

Description:

patients with AML prior and after treatment